Sure, the antibodies market is booming — but it’s not without its growing pains. One big challenge is cost. Developing and producing biologic drugs can be expensive, and that cost sometimes gets passed on to patients. That’s a real issue in countries where healthcare coverage isn’t universal. Another challenge is regulatory complexity — getting approvals for new...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Tiếng Việt